Skip to main content
New small molecules targeting castration-resistant prostate cancer

New small molecules targeting castration-resistant prostate cancer

Unmet Need Prostate cancer (PC) is the second most common male cancer globally and represents 15% of all cancers diagnosed in males. An estimated 34,700 deaths were predicted to occur from PC in the U.S.…

Read More

Topical MEK inhibition as a new modality for inflammatory skin diseases and cancers

Topical MEK inhibition as a new modality for inflammatory skin diseases and cancers

Unmet Need Inflammatory skin conditions affect many people, with a wide range of severities. Common skin disorders, such as psoriasis and atopic dermatitis, affect close to 20% of the population. Skin lesions associated with bone…

Read More

Method to sensitize cancer radiotherapy and chemotherapy

Method to sensitize cancer radiotherapy and chemotherapy

Unmet Need While radiotherapy and/or chemotherapy are used for >90% of cancer patients in clinical settings, the therapeutic outcomes are far from ideal for many types of tumors due to the development of drug resistance…

Read More

A class of biodegradable stealth polymers to improve drug delivery

A class of biodegradable stealth polymers to improve drug delivery

Unmet Need Delivery of drugs or therapeutics such as small molecules, peptides, and proteins, in their native form, is limited by their poor stability, low solubility, and short in vivo circulation. These challenges in drug…

Read More

A method for treating TRAIL-resistant cancers

A method for treating TRAIL-resistant cancers

Unmet Need Over the past twenty years, TNF-related apoptosis-inducing ligand (TRAIL) has been shown to kill a variety of human cancer cells in vitro and in vivo while remaining innocuous to healthy cells. Unfortunately, the…

Read More

A tumor-targeting delivery method for chemotherapeutics and other cargo

A tumor-targeting delivery method for chemotherapeutics and other cargo

Unmet Need Delivery and therapeutic efficacy of small molecule imaging agents and chemotherapeutics are hampered by their short half-life, low solubility, non-selectivity to cancer cells, and toxic side effects. Small molecule chemotherapeutics, although in routine…

Read More

A nanoparticle drug delivery system for small molecule cancer drugs that binds endogenous albumin

A nanoparticle drug delivery system for small molecule cancer drugs that binds endogenous albumin

Unmet Need Small molecule cancer drugs often suffer from poor systemic exposure, resulting from their low water solubility and short plasma half-life. Additionally, the off-target toxicity is the main challenge that undermines efficacy. Nanoparticle drug…

Read More

Targeting drugging molecules that promote cancer metastasis

Targeting drugging molecules that promote cancer metastasis

Value Proposition Metastases, the spread of cancer cells to new areas of the body, are common and devastating complications of many kinds of cancers. For instance, bone metastasis occurs in 73% of advanced breast cancer…

Read More

Avicins and thioesterification to control protein function

Avicins and thioesterification to control protein function

Value Proposition Thioesterification agents can modify cysteine groups of signaling proteins in order to modify their activity. Pathologies that could benefit from such protein modifications, which modulate physiologic redox status, include atherosclerosis, cancer, bacterial infections,…

Read More

Novel therapeutic targets in the androgen receptor signaling pathway for prostate cancer

Novel therapeutic targets in the androgen receptor signaling pathway for prostate cancer

Unmet Need Prostate cancer is the most common malignancy in men. The most recent CDC data demonstrates that prostate cancer makes up 12.2% all new cancer cases in the U.S. at 207,430. Prostate cancers express…

Read More

A rod-like nanoparticle drug delivery system for hydrophilic small molecules

A rod-like nanoparticle drug delivery system for hydrophilic small molecules

Unmet Need New strategies to load small molecule drugs into nanoparticles are a powerful approach to improve the therapeutic efficacy of chemotherapeutics, and this has been a successful strategy for overcoming the limitations of poor…

Read More

Improving immune checkpoint therapies for cancer by inhibiting the PCSK9 protein

Improving immune checkpoint therapies for cancer by inhibiting the PCSK9 protein

Value Proposition Immune checkpoint inhibitor therapies are exciting new drugs for treatment of cancers. Despite their efficacy for certain cancers, immune checkpoint inhibitors only effective in 10-30% of cancer patients. Because of this, there is…

Read More

Have Questions?

Please contact us or subscribe for more opportunities

Stay in Touch with Us